Ireland
--:--IST
Recruiting Observational

AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging

NCT07551466 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2026-05-01
Last updated
2026-04-24

Condition(s) studied

Early Gastric Cancer

Investigational drug(s) / intervention(s)

No intervention (observational study)

No intervention (observational study): This is an observational study with no intervention assigned to participants.

Study summary

Early gastric cancer (EGC) is often difficult to detect accurately during endoscopic examination due to subtle morphological features and variability among endoscopists. Artificial intelligence (AI) has shown promise in improving diagnostic performance; however, most existing models lack interpretability and rely on single-modality imaging.

This study aims to develop and evaluate an explainable multimodal artificial intelligence model for the diagnosis of early gastric cancer using endoscopic imaging. The model integrates features derived from white-light imaging and image-enhanced endoscopy, along with quantitative image features and clinical data, to improve diagnostic accuracy and provide interpretable decision support.

The primary outcome is the diagnostic performance of the AI model for detecting early gastric cancer, evaluated by area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity.

The results of this study are expected to provide evidence for the clinical utility of explainable AI in endoscopic diagnosis and support the development of reliable human-AI collaborative diagnostic systems.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Suspicious gastric lesions identified on white-light imaging (WLI) * Preoperative biopsy indicating precancerous lesions (dysplasia or intraepithelial neoplasia) or adenocarcinoma, with preoperative magnifying endoscopy with narrow-band imaging (ME-NBI) performed * Patients meeting the absolute indications for endoscopic submucosal dissection (ESD) and who underwent ESD Exclusion Criteria: * Non-adenocarcinoma histological types (e.g., lymphoma) * Patients who did not undergo ME-NBI examination or did not receive ESD * Lesions invading the muscularis propria or deeper layers * Missing or indeterminate postoperative histopathological results

Primary outcome measure(s)

  • Diagnostic performance of the artificial intelligence model for detecting early gastric cancer — Up to 14 days after endoscopy, when histopathological results are available
    The primary outcome is the diagnostic performance of the artificial intelligence model for identifying early gastric cancer, evaluated by the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, accuracy, and F1 score, using histopathological diagnosis as the reference standard.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Soochow University Suzhou China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07551466 on ClinicalTrials.gov ↗ ← All trials in China